All In Biotech

Drug Trial Radar · NCT03960788

Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer

Gadoxetate Sodium Enhanced Magnetic Resonance Imaging (MRI) as a Biomarker for Aggressive Prostate Cancer

Last checked: Nov 20, 2026Latest source record: May 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

50

Planned (sponsor's estimate)

Start

Jan 2, 2018

Primary completion

Jan 2, 2020

Study completion Jan 2, 2021

Sponsor

Lead sponsor
University of CincinnatiAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 23, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to test to see if Gadoxetate Sodium is a useful contrast agent for detecting prostate cancer during magnetic resonance imaging (MRI). Gadoxetate Sodium is an FDA approved contrast agent that is currently used to detect liver cancer. Gadoxetate Sodium shows promise in identifying more aggressive prostate cancers at earlier stages. The study will also test to see if specific genes are expressed in the left over tissue samples from previous prostate fusion biopsy. The investigators hypothesize that Gadoxetate Sodium-enhanced MRI can differentiate aggressive prostate cancer and predict its early recurrence.

Conditions

  • Cancer of the Prostate
  • Castration-resistant Prostate Cancer

Interventions

  • Gadoxetate SodiumDrug

    Gadoxetate Sodium is an FDA approved contrast agent to be used during magnetic resonance imaging.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of Gadoxetate Sodium to gadolinium in effectiveness of identification of prostate cancer as measured by contrast enhancement ratiosTime frame: 3 weeks from consent

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Cincinnati

    Cincinnati, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.